



## Prior Authorization Criteria

### JASCAYD® (nerandomilast) PA CRITERIA:

JASCAYD® (nerandomilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for:

- the treatment of idiopathic pulmonary fibrosis in adult patients
- the treatment of progressive pulmonary fibrosis in adult patients

Prior authorization is required for JASCAYD® (nerandomilast). Prior authorization approval will be considered when the following criteria are met. Along with the Universal PA Form, please submit any supporting clinical documentation.

#### Initial Authorization: 12 Months

1. The patient must meet the minimum age requirements recommended by the package insert for FDA approved indication; **AND**
2. The patient has a diagnosis of:
  - a. idiopathic pulmonary fibrosis consistent with current guidelines (e.g., American Thoracic Society/European Respiratory Society/Japanese Respiratory Society) and the prescriber attests that other underlying causes for pulmonary fibrosis have been ruled out; **OR**
  - b. progressive pulmonary fibrosis consistent with current guidelines (e.g., American Thoracic Society/European Respiratory Society/Japanese Respiratory Society); **AND**
3. The patient has a baseline Forced Vital Capacity  $\geq$  45% of predicted; **AND**
4. Prescribed by or in consultation with a pulmonologist or another healthcare provider experienced in treating pulmonary fibrosis or related conditions; **AND**
5. The patient has tried and had an inadequate response to all preferred agents under the same PDL drug class that are indicated for the diagnosis; **AND**
6. Prescribed dose does not exceed 2 tablets per day.



**Re-Authorization:** 12 Months

1. Patient continues to meet initial authorization criteria; **AND**
2. Prescribed dose does not exceed 2 tablets per day; **AND**
3. Positive clinical response to therapy

**JASCAYD® (nerandomilast) Dosing:**

- The recommended dose is 18mg every 12 hours. If not tolerated, may decrease dose to 9 mg every 12 hours except in persons receiving concomitant pirfenidone.

**Formulation:**

- JASCAYD® is available as 9mg or 18mg oral tablets.